A single-blind, randomized, crossover study on the efficacy of icatibant for sweating-induced dermal pain (icatibant for sweating-induced dermal pain)

What Was Tested

Researchers studied Bradykinin and Icatibant in this randomized controlled trial publication.

The pathomechanism underlying the sweating-induced dermal pain remains poorly understood and there exists no standard treatment for such pain.

Who Took Part

Ten patients will be enrolled and assigned randomly in a 1:1 ratio to either the icatibant-placebo or placebo-icatibant groups.

The primary endpoint is the change in the visual analog scale scores for dermal pain induced by thermal load before and after treatment with icatibant or placebo.

How the Study Was Run

The researchers set it up as a randomized, single-blind, placebo-controlled, crossover and multicenter study.

Random assignment meant chance, not the researchers, decided who got Bradykinin and who got the comparison, which limits bias.

Only one side, usually the participants, was kept unaware of whether Bradykinin was given.

A placebo (an inactive look-alike) gave the Bradykinin group a baseline to be compared against.

Each person switched between Bradykinin and the comparison at some point, usually with a gap in between.

Secondary endpoints include changes in the duration of dermal pain, blood and plasma histamine levels, serum angiotensin-converting enzyme levels, and histological evaluation of skin tissue samples at the site of dermal pain.

What Was Measured

Topics PubMed links to this paper include Bradykinin, Quality of Life, Sweating and Pain.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Bradykinin and Icatibant.

Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Medicine), a journal based in United States.

More context: the Bradykinin compound page and the Icatibant compound page, all human trials.